Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Date publication

janvier 2025

Journal

Journal for immunotherapy of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HERVIEU Alice

Tous les auteurs :
Frenel JS, Mathiot L, Cropet C, Borcoman E, Hervieu A, Coquan E, De La Motte Rouge T, Saada-Bouzid E, Sabatier R, Lavaud P, Jimenez M, Legrand F, Le Saux O, Charafe E, Gonçalves A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39773562

Résumé

The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort.

Mots clés

Cervical Cancer, Chemotherapy, Immune Checkpoint Inhibitor

Référence

J Immunother Cancer. 2025 01 7;13(1):